The clinical pharmacist participated in the treatment of a patient with urinary tract infection caused by Enterococcus casseliflavus, and it was not effective after empirical treatment with piperacillin sodium tazobactam sodium. Ticoplanin was used according to the drug sensitivity results, but the patient had rare adverse reactions of thrombocytopenia, and the clinical pharmacist recommended to give the patient daptomycin anti-infection therapy according to the characteristics of the pathogen and the renal concentration of the drug, then the patient's condition gradually improved. In this case, clinical pharmacists combined pharmaceutical theory with clinical practice, and put forward reasonable suggestions for clinical diagnosis, reasonable drug selection and treatment plan adjustment, so as to bring the patient's infection under control. The participation of clinical pharmacists has promoted clinical rational drug use and plays a positive role in the treatment of patients.

1.谢琴秀, 熊自忠. 21例铅黄肠球菌感染的临床特征分析[J]. 安徽医药, 2008, 12(10): 925-926. [Xie QX, Xiong ZZ. Clinical analysis of 21 cases with infection of enterococcus casseliflavus[J]. Anhui Medical and Pharmaceutical Journal, 2008, 12(10): 925-926.] DOI: 10.3969/j.issn.1009-6469.2008.10.021.

2.陈杏凯, 张海霞. 利奈唑胺群体药动学的文献分析[J]. 中南药学, 2021, 19(1): 158-161. [Chen XK, Zhang HX. Research progress of linezolid in population pharmacokinetics[J]. Central South Pharmacy, 2021, 19(1): 158-161.] DOI: 10.7539/j.issn.1672-2981.2021.01.031.

3.陈娜, 陈书斌, 蒋鹏, 等. 替加环素的群体药动学研究进展[J]. 中国药学杂志, 2021, 56(13): 1035-1040. [Chen N, Chen SB, Jiang P, et al. Population pharmacokinetics of tigecycline[J]. Chinese Pharmaceutical Journal, 2021, 56(13): 1035-1040.] DOI: 10.11669/cpj.2021.13.002.

4.张华华, 王江峰, 范辉, 等. 以《中国药品综合评价指南参考大纲》为依据对达托霉素进行综合评价--体内药学特性评价[J]. 药品评价, 2016, 13(8): 8-12, 59. [Zhang HH, Wang JF, Fan H, et al.Comprehensive evaluation of daptomycin based on the Guideline for Comprehensive Drug Evaluation in China-in vivo pharmaceutical characteristics evaluation[J]. Drug Evaluation, 2016, 13(8): 8-12, 59. ] DOI: 10.3969/j.issn.1672-2809.2016.08.001.

5.达托霉素临床应用专家意见编写专家组, 中国研究型医院学会感染性疾病循证与转化专业委员会. 达托霉素临床应用专家意见[J]. 中国感染控制杂志, 2019, 18(11): 989-1003. DOI: 10.12138/j.issn.1671-9638.20195182.

6.魏寒松, 王永宁, 陈曼萍. 尿路感染中病原体致病因素的研究进展[J]. 中华微生物学和免疫学杂志, 2021, 41(4): 322-326. [Wei HS, Wang YN, Chen MP. Advances in bacteria-related pathogenic factors in urinary tract infections[J]. Chinese Journal of Microbiology and Immunology, 2021, 41(4): 322-326.] DOI: 10.3760/cma.j.cn112309-20200804-00387.

7.石继春,  陈驰, 梁丽, 等. 铅黄肠球菌CMCC(B)32220的鉴定和全基因组分析[J]. 临床检验杂志, 2022, 40(2): 116-119. [Shi JC, Chen C, Liang L, et al. Identification and whole genome analysis of Enterococcus casseliflavus CMCC(B)32220[J]. Chinese Journal of Clinical Laboratory Science, 2022, 40(2): 116-119.] DOI: 10.13602/j.cnki.jcls.2022.02.08.

8.Vasilakopoulou A, Vourli S, Siafakas N, et al. Enterococcus casseliflavus bacteraemia in a patient with chronic renal disease[J]. Infect Dis Rep, 2020, 12(3): 70-73. DOI: 10.3390/idr12030015.

9.蒋筱漪, 刘颖, 李凤敏. 肠球菌的耐药分析及药物监测的重要性[J]. 中国医学研究与临床, 2006, 4(4): 45-46. [Jiang XY, Liu Y, Li FM. Importance of drug resistance analysis and drug surveillance in Enterococci[J]. Chinese Medical Research & Clinical, 2006, 4(4): 45-46.] https://d.wanfangdata.com.cn/periodical/QK200602727128.

10.Verma R, Baroco AL. Enterococcus casseliflavus septicaemia associated with hepatobiliary infection in a 75-year-old man[J]. BMJ Case Rep, 2017, 2017: bcr2017219636. DOI: 10.1136/bcr-2017-219636.

11.梁玉梅, 黄安兰, 殷薇. 替考拉宁治疗革兰阳性菌引起的复杂性尿路感染疗效观察[J]. 中华医院感染学杂志, 2009, 19(24): 3414-3416. [Liang YM, Huang AL, Yin W. Efficacy of teicoplanin treatment on complicated gram-positive urinary tract infection[J]. Chinese Journal of Nosocomiology, 2009, 19(24): 3414-3416.] DOI: CNKI:SUN:ZHYY.0.2009-24-050.

12.储淼, 徐志宏, 蒋青. 替考拉宁致血小板减少[J]. 药物不良反应杂志, 2012, 14(1): 47-48. [Chu M, Xu ZH, Jiang Q. Teicoplanin-induced thrombocytopenia[J]. Adverse Drug Reactions Journal, 2012, 14(1): 47-48.] DOI: 10.3969/j.issn.1008-5734.2012.01.018.

13.殷敏. 临床菌株铅黄肠球菌EC369分子特征及比较基因组学分析[D]. 浙江温州: 温州医科大学, 2019.

14.李晓端, 程刚英, 阚清, 等. 1例疑似替考拉宁导致血小板减少的用药分析 [J] . 中国药师, 2019, 22(2) : 305-308. [Li XR, Cheng GY, Kan Q, et al. Analysis of a case of suspected thrombocytopenia caused by teicoplanin[J]. China Pharmacist, 2019, 22(2): 305-308.] DOI: 10.3969/j.issn.1008-049X.2019.02.029.

15.胡田田, 陶艳玲. 达托霉素用于治疗缓症链球菌血症并化脓性脑膜炎1例[J]. 中国感染与化疗杂志, 2022, 22(2): 220-222. [Hu TT, Tao YL. Daptomycin for the treatment of Streptococcus mitis bacteremia and purulent meningitis: a case report[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(2): 220-222.] DOI: 10.16718/j.1009-7708.2022.02.020.

16.Brauers J, Kresken M, Menke A, et al. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations[J]. Int J Antimicrob Agents, 2007, 29(3): 322-325. DOI: 10.1016/j.ijantimicag.2006.10.003.

17.任晓蕾, 张海英, 李玉珍. 环脂肽类抗生素达托霉素[J]. 中国新药杂志, 2009, 18(12): 1075-1077, 1080. [Ren XL, Zhang HY, Li YZ. Daptomycin: one of the cyclo-lipopeptide antibiotics[J]. Chinese Journal of New Drugs, 2009, 18(12): 1075-1077, 1080.] DOI: 10.3321/j.issn:1003-3734.2009.12.002.